U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Showing 1 - 10 of 24 results

Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...
Status:
US Approved Rx (1986)
First approved in 1985

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic, used especially for Pseudomonas and other gram-negative infections in debilitated patients. Ceftazidime is used to treat lower respiratory tract, skin, urinary tract, blood-strea...
Status:
US Approved Rx (2011)
First approved in 1985

Class (Stereo):
CHEMICAL (ABSOLUTE)



Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem has a broad spectrum of activity against aerobic and anaerobic Gram positive as well as Gram negative bacteria. It is particularly important for its activity aga...
Status:
Investigational

Class (Stereo):
CHEMICAL (ABSOLUTE)


Sulopenem is a thiolanylthiopenem derivative patented by American multinational pharmaceutical corporation Pfizer Inc as an antibiotic with broad-spectrum antibacterial activity against most gram-positive and gram-negative bacteria. Sulopenem showed ...
Status:
US Previously Marketed
First approved in 1995

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ceftibuten is a 3rd generation cephalosporin that is FDA approved for the treatment of acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis. Ceftibuten exerts its bactericidal action by bindin...
Status:
US Previously Marketed
First approved in 1988

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cefotiam is a third generation beta-lactam cephalosporin antibiotic. It has broad spectrum activity against Gram positive and Gram negative bacteria. It does not have activity against Pseudomonas aeruginosa. The bactericidal activity of cefotiam resu...
Status:
US Previously Marketed
First approved in 1984

Class (Stereo):
CHEMICAL (ABSOLUTE)



Amdinocillin is a novel, semisynthetic penicillin effective against many gram-negative bacteria. The antibacterial activity of amdinocillin is derived from its ability to bind specifically and avidly to Penicillin Binding Protein-2 (PBP 2). Amdinocil...
Status:
Possibly Marketed Outside US

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cefodizime is a third-generation cephalosporin with a broad spectrum of antibacterial activity. Administered intravenously or intramuscularly 1 to 4 g of cefodizime daily for an average of 7 to 10 days produces a clinical cure in 80 to 100% of patien...
Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...
Status:
US Approved Rx (2018)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz. The bactericidal activity of ertapenem results from the inhibition of cell wall synthesis and is mediated through ertapenem binding to penicillin binding proteins (PBPs). In Escherichi...